Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Increased HCV testing and treatment for both HIV-positive and HIV-negative gay and bi men could help eliminate hep C.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
Alcoholism-related liver disease was a growing problem even before COVID-19, but the pandemic has dramatically added to the toll.
Hepatitis A and E usually resolve on their own, but hepatitis B and C can cause serious liver disease, including cirrhosis and liver cancer.
Fat in the liver can lead to health complications, including cirrhosis and liver cancer.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
Hepatitis A and B can be prevented with vaccines, and hepatitis C can be cured with antiviral treatment.
Non-alcoholic fatty liver disease is more common among those with the virus compared with the general population.
A recent Swedish study defined a low-level detectable viral load as between 50 and 999.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
In the era of highly effective treatments for both viruses, HIV doesn’t speed the advancement of cirrhosis.
The indication for AbbVie’s regimen includes those with compensated cirrhosis.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.